Century Therapeutics to present data from Phase 1 ELiPSE-1 trial of CNTY-101

Century Therapeutics announced the upcoming presentation of initial data from its ongoing first-in-human Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory CD19 positive B-cell lymphomas. The data, which support the potential for a multi-dosing strategy for CAR iNK enabled by Allo-Evasion edits, will be featured during a poster session at the 65th American Society of Hematology Annual Meeting and Exposition being held December 9-12, 2023 in San Diego. A copy of the abstract, which highlights a case study of a patient with high risk relapsed/refractory follicular lymphoma who completed four 28-day cycles of CNTY-101 as of a July 10, 2023 data cutoff, is now available online. The patient, who received four prior lines of therapy, completed four 28-day cycles of CNTY-101 at the 100 million cell dose level, the first two of which were administered following lymphodepletion while the most recent two were administered without lymphodepletion. CNTY-101 was well tolerated, with no measurable functional pre-existing or induced anti-drug-antibodies observed. Pharmacokinetic measurements demonstrated that CNTY-101 cells were detected after each infusion with comparable kinetics, with a limited duration in circulation.Updated data to be announced in December will include additional results from patients treated at Dose Level 1 as of a more recent cutoff date, as well as preliminary data from patients treated at the 300 million cell dose level. “We are thrilled to share the first clinical evidence supporting the potential for our proprietary Allo-Evasion technology to engineer differentiated allogeneic cell therapies capable of delivering a multi-dosing regimen,” said Adrienne Farid, Ph.D., Chief Operations Officer and Head of Early Development at Century Therapeutics. “While this is a significant achievement in and of itself, data also demonstrate that CNTY-101 is, to our knowledge, the first therapy of its kind to be re-dosed without lymphodepletion, a procedure commonly associated with high rates of toxicity. We look forward to sharing additional patient data next month which we believe will continue to support the potential for Century to deliver novel cell therapies with increased drug exposure via a multi-dosing approach to ultimately drive deeper and more durable responses. The potential of our platform to enable dosing without lymphodepletion is particularly exciting for both oncology and non-oncology indications, where the side effect profile of lymphodepletion may be prohibitive.”